There also exists an impressive body of work demonstrating the biomarker’s efficacy as a cancer imaging and diagnostic tool, ranging from radio-labeled CEA antibodies [66–71] to the use of fluorescent labels [72–79]. This evidence concerns the gene CEACAM5 and cancer.